Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CAR-TNK
- Development stage
- Preclinical
- Lead developer
- Sorrento Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intracerebroventricular
01
Overview
**CD19-CAR-TNK** is a preclinical, off-the-shelf CD19-directed chimeric antigen receptor natural killer cell therapy developed through a collaboration between Conkwest and Sorrento Therapeutics. The proposed product uses Conkwest's NK-92-derived Neukoplast cell line as the cytotoxic effector population and incorporates a Sorrento-designed CAR intended to recognize CD19, a B-cell surface antigen. CD19-directed CAR-TNK cells were proposed for B-cell hematologic malignancies as part of a broader CAR-TNK program intended to provide scalable allogeneic cell immunotherapy with potentially lower cytokine-release risk than patient-derived CAR-T-cell products.
- Other names
- CD19-CAR.TNKCD-19-CAR.TNKCD 19-CAR.TNKCD19-CAR-TNKCD-19-CAR-TNKCD 19-CAR-TNK
02
Targets
Beyond the preview
Go deeper on CD19-CAR-TNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-CAR-TNK.